Nalirinox Neo-pancreas RAS Mut ctDNA Study

NCT04010552 | Unknown Phase 2

• 1 other identifier: FiHM006
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 3

Brief Summary

Pancreatic cancer has an unfavorable prognosis with a reduced possibility of long-term survival. The only treatment with curative potential is surgery, but it is only possible in 15-20% of cases. There are patients with clear criteria for surgical entry, others at the limit of the possibility of surgery, and patients with such advanced disease (either locally or with metastasis) that surgery is not indicated. The objective of neoadjuvant chemotherapy treatment (received before surgery) is to reduce the tumor before surgery and reduce the risk of subsequent metastases and local recurrences, in borderline tumors or those resectable with high-risk criteria. The FOLFIRINOX scheme, composed of 5-fluorouracil / folinic acid, oxaliplatin and irinotecan, is recommended as neoadjuvant treatment, but the response is still low. This study will use a modified FOLFIRINOX (NALIRINOX) regimen with a form of irinotecan attached to liposomes that allows greater action on tumor cells. Mutations in the KRAS gene are associated with a greater growth capacity of tumor cells and are present in 90% of pancreatic cancers in advanced stages. They would be less frequent in earlier phases but little is known about the impact that chemotherapy treatment and subsequent surgery could have on the increase or decrease of these mutations, as well as their implication. The follow-up of these mutations with repeated pancreatic biopsies is not viable, but it can be monitored by simple blood samples in which the genetic material of the tumor can be analyzed.

Conditions

Resectable Pancreatic Ductal Adenocarcinoma

Outcome Measures

Primary Outcomes (1)

• Proportion of subjects with a good histological tumour response in the resected specimens after neoadjuvant chemotherapy with NALIRINOX and surgical removal according to the Ryan's classification in KRAS positive and negative patients

  8 weeks after surgical intervention

Secondary Outcomes (11)

• R0 resection

  Through the study completion (estimated to be 15 months)

• 1-year survival and Overal survival (OS) in baseline KRAS+ and KRAS- subjects

  Through the study completion (estimated to be 15 months)

• Progression Free Survival (PFS)

  Through the study completion (estimated to be 15 months)

• Assessment of the proportion of KRAS- subjects switching to KRAS+ (and from KRAS+ to negative) after neoadjuvant NALIRINOX

  Through the study completion (estimated to be 15 months)

• Assessment of the number of KRAS- subjects switching to KRAS+ (and from KRAS+ to negative) after neoadjuvant NALIRINOX

  Through the study completion (estimated to be 15 months)

Study Arms (1)

NALIRINOX treatment

EXPERIMENTAL

Patients will be treated with NALIRINOX, a combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin. Treatment regimen will consist of 8 cycles of neoadjuvant NALIRINOX prior to surgery and trial duration is expected to be 24 months.

Drug: NALRINOX combination

Interventions

NALRINOX combination DRUG

NALRINOX: combination of three chemotherapy agents: 5- FU/LV, nal-IRI, and oxaliplatin

NALIRINOX treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or females, aged 18 years or older
• Histologically or cytologically confirmed diagnosis of PDAC
• Candidates for pancreatic cancer surgery (no comorbidities that can exclude for surgery)
• Life expectance of at least 12 months
• Carbohydrate antigen 19-9 (CA19-9) levels \< 500 U/ml
• ECOG performance status ≤ 1
• Adequate bone marrow function:
• Hemoglobin \>9 g/dL
• Platelets \>100.000 µL
• Absolute neutrophil count (ANC) \>1500 µl
• Serum albumin \> 3 g/dL
• Adequate hepatic function:
• Aspartate aminotransferase (AST) \<3 upper limits of normal (ULN)
• Alanine Aminotransferase (ALT) \<3 ULN
• Total Bilirubin \< 1.5 ULN. If values are \> 1.5 external drainage with a stent is allowed.

You may not qualify if:

• Patients with metastatic disease
• Patients ≥ 75 years.
• Uncontrolled coagulopathy
• Patients with a contraindication to surgery (locally advanced disease or patients not amenable to pancreatic surgery due to a previous comorbidity)
• Patients with prior or concurrent malignant disease that required treatment with chemotherapy in the past.
• Previous cytotoxic therapy within 36 months for other no-cancer disease (ie arthritis rheumatoid)
• Known or suspected reactions to any component of the study medication (5-FU/LV, nal- IRI or oxaliplatin) or to components of similar chemical or biologic composition
• Concurrent participation in any other clinical trial likely to interfere with the therapeutic schedule
• Human immunodeficiency virus (HIV) positivity, active Hepatitis B or Hepatitis C infection.
• Uncontrolled illness including ongoing or active infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, myocardial infarction, or left ventricular ejection fraction (LVEF) \< 50, among others, or psychiatric illness/social situations that would limit compliance with study requirements.
• Pregnant or breast-feeding women.
• Any medical condition that, based on investigator's criteria, places the subject at risk, makes the subject ineligible or may jeopardize protocol compliance.

Sponsors & Collaborators

• Fundación de investigación HM: lead
• Syntax for Science, S.L: collaborator

Study Sites (3)

Hestia Duran I Reynals

L'Hospitalet de Llobregat, Barcelona, 08908, Spain

Location

Hospital Universitario Madrid Sanchinarro

PAU de Sanchinarro, Madrid, 28050, Spain

Location

Hospital Universitari Vall D'Hebron

Barcelona, 80034, Spain

Location

Study Officials

• Antonio Cubillo, MD

  Director

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: This study is a multicenter, single-arm, interventional, open-label, non-randomized, phase II clinical trial, to evaluate the association of KRAS mutational load and histological tumour response after chemotherapy treatment in patients with PDAC. Due to its single-arm design patients will be assigned to a single group (non-randomized) and there will be no masking (open-label).

Study Record Dates

• First Submitted: July 3, 2019
• First Posted: July 8, 2019
• Study Start: May 1, 2019
• Primary Completion: August 1, 2023
• Study Completion: November 1, 2023
• Last Updated: August 2, 2022

Record last verified: 2022-07

Locations

ES (3)